Melanie Adams, Sze Wah Samuel Chan
1. Invasive disease-free survival was significantly higher in patients receiving adjuvant ribociclib + NSAI when compared to patients receiving NSAI alone.
2. Distant disease-free survival and recurrence-free survival also favoured treatment with adjuvant ribociclib + NSAI, compared to NSAI alone.
Evidence Rating Level: 1 (Excellent)
Study Rundown: In this phase 3, randomized, international, open-label trial, 5101 patients with stage II or III HR-positive, HER2-negative breast cancer were assigned to receive either, a reduced dose ribociclib (400 mg PO OD x 21 days, followed by 7 days off x 3 years) + NSAI or to receive NSAI alone (anastrozole)...
March 25, 2024: 2 Minute Medicine